In order to guide the scientific research, development and evaluation of antiviral drugs for COVID-19 and provide technical standards for reference, the CDE has formulated the Technical Guidance for Clinical Trials of New Antiviral Drugs for COVID-19 (Interim). According to the requirements of the Notice of the NMPA Comprehensive Department on Printing and Issuing the Release Procedures for Drug Technical Guidance, the Guidance was issued for implementation on February 8, 2022 upon review and approval by NMPA.